
|Videos|April 5, 2017
FGFR Inhibitor Shows Preclinical Activity in Breast Cancer
Author(s)Dominik Mumberg, PhD
This video highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
Advertisement
In this video, Dominik Mumberg, PhD, of Bayer AG in Berlin, highlights preclinical activity of a novel FGFR inhibitor that has been tested alone and in combination with antihormonal therapy in breast cancer cell lines.
The data were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease
2
Lu-PSMA-617/Pembrolizumab Shows Early Efficacy in Metastatic CRPC
3
Developers Submit NDA for Neladalkib in Pretreated ALK+ NSCLC
4
Navigating ADC Sequencing Beyond the First Line in Breast Cancer
5





















































